High Oxygen Delivery to Preserve Exercise Capacity in IPF Patients Treated With Nintedanib: The HOPE-IPF Study
Status: Recruiting
Location: See all (8) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The purpose is to determine if patients with idiopathic pulmonary fibrosis (IPF) taking nintedanib will have improved exercise endurance, breathlessness and quality of life if breathing 60% oxygen compared to standard of care during an 8 week exercise training program.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 19
Healthy Volunteers: f
View:
• Age 19 years or older
• Idiopathic Pulmonary Fibrosis (IPF) diagnosis according to American Thoracic Society and/or European Respiratory Society consensus criteria
• Appropriate candidate for pulmonary rehabilitation
• prescribed nintedanib by their treating physician or currently on nintedanib
• 6 minute walk distance 50m or more
• Oxygen saturation 92% or more by pulse oximetry at rest while breathing room air
• Clinically stable for the preceding 6 weeks
Locations
Other Locations
Canada
University of Calgary
COMPLETED
Calgary
University of Alberta
RECRUITING
Edmonton
McMaster University
RECRUITING
Hamilton
UBC Okanagan
COMPLETED
Kelowna
Queens University
COMPLETED
Kingston
McGill University
COMPLETED
Montreal
Laval University
COMPLETED
Québec
St. Paul's Hospital
RECRUITING
Vancouver
Contact Information
Primary
Lynda Lazosky
llazosky@btrg.ca
604-682-2344
Backup
Satvir S Dhillon, MSc
satvir.dhillon@hli.ubc.ca
604-806-8835
Time Frame
Start Date: 2015-12
Estimated Completion Date: 2026-12
Participants
Target number of participants: 88
Treatments
Experimental: 60% Oxgyen
While participants are exercising, they will be breathing 60% oxygen through a mask.
Placebo_comparator: Standard of Care
While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
Related Therapeutic Areas
Sponsors
Collaborators: Boehringer Ingelheim
Leads: University of British Columbia